NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

8 brokers have issued 12-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' share price to reach $36.57 in the next year. This suggests a possible upside of 56.4% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

Media headlines about ITCI stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 8,370,000 shares, a decrease of 34.9% from the December 15th total of 12,850,000 shares. Based on an average trading volume of 2,640,000 shares, the short-interest ratio is currently 3.2 days. Currently, 17.9% of the company's shares are sold short. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Deciphera Pharmaceuticals (DCPH) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), AbbVie (ABBV), Myovant Sciences (MYOV), GW Pharmaceuticals PLC- (GWPH) and Zynerba Pharmaceuticals (ZYNE).

Intra-Cellular Therapies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.61%), Rhenman & Partners Asset Management AB (0.90%), First Midwest Bank Trust Division (0.18%), Assenagon Asset Management S.A. (0.03%), Gainplan LLC (0.02%) and Janney Montgomery Scott LLC (0.01%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Candriam Luxembourg S.C.A.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Assenagon Asset Management S.A., Gainplan LLC, Janney Montgomery Scott LLC and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $23.38.

Intra-Cellular Therapies has a market capitalization of $1.30 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]